Ideaya Biosciences Shares Jump on Trial Results

Dow Jones

Apr 13

By Connor Hart

Shares of Ideaya Biosciences climbed after the company announced what it called positive top-line results from its melanoma-treatment trial.

The stock jumped 36%, to $41.52, in premarket trading Monday. Through Friday's close, shares are up 82% over the past year.

The oncology company said before the bell that its treatment, darovasertib, used in combination with crizotinib, resulted in a statistically significant improvement in median progression-free survival in patients with a certain type of melanoma in a Phase 2/3 registrational study with pharmaceutical group Servier.

"For patients with uveal melanoma, these results potentially offer a new treatment option that delivers a significant clinical advancement in both progression-free survival and overall response rate versus currently available therapies," Chief Executive Yujiro Hata said.

Ideaya said that, based on these results, it will target the submission of a new drug application to the Food and Drug Administration in the second half of the year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

April 13, 2026 06:35 ET (10:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2627434633"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627434633\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627434633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627434633","market":"hk","top_or_hot":-1,"title":"Ideaya Biosciences Shares Jump on Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Ideaya Biosciences climbed after the company announced what it called positive top-line results from its melanoma-treatment trial. \n</p>\n<p>\n  The stock jumped 36%, to $41.52, in premarket trading Monday. Through Friday's close, shares are up 82% over the past year. \n</p>\n<p>\n  The oncology company said before the bell that its treatment, darovasertib, used in combination with crizotinib, resulted in a statistically significant improvement in median progression-free survival in patients with a certain type of melanoma in a Phase 2/3 registrational study with pharmaceutical group Servier. \n</p>\n<p>\n  \"For patients with uveal melanoma, these results potentially offer a new treatment option that delivers a significant clinical advancement in both progression-free survival and overall response rate versus currently available therapies,\" Chief Executive Yujiro Hata said. \n</p>\n<p>\n  Ideaya said that, based on these results, it will target the submission of a new drug application to the Food and Drug Administration in the second half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 13, 2026 06:35 ET (10:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ideaya Biosciences Shares Jump on Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIdeaya Biosciences Shares Jump on Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-13 18:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Ideaya Biosciences climbed after the company announced what it called positive top-line results from its melanoma-treatment trial. \n</p>\n<p>\n  The stock jumped 36%, to $41.52, in premarket trading Monday. Through Friday's close, shares are up 82% over the past year. \n</p>\n<p>\n  The oncology company said before the bell that its treatment, darovasertib, used in combination with crizotinib, resulted in a statistically significant improvement in median progression-free survival in patients with a certain type of melanoma in a Phase 2/3 registrational study with pharmaceutical group Servier. \n</p>\n<p>\n  \"For patients with uveal melanoma, these results potentially offer a new treatment option that delivers a significant clinical advancement in both progression-free survival and overall response rate versus currently available therapies,\" Chief Executive Yujiro Hata said. \n</p>\n<p>\n  Ideaya said that, based on these results, it will target the submission of a new drug application to the Food and Drug Administration in the second half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 13, 2026 06:35 ET (10:35 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDYA","symbol_name":"IDEAYA Biosciences","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627434633","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627434633","pubTimestamp":1776076500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Ideaya Biosciences climbed after the company announced what it called positive top-line results from its melanoma-treatment trial.The stock jumped 36%, to $41.52, in premarket trading Monday. Through Friday's close, shares are up 82% over the past year.The oncology company said before the bell that its treatment, darovasertib, used in combination with crizotinib, resulted in a statistically significant improvement in median progression-free survival in patients with a certain type of melanoma in a Phase 2/3 registrational study with pharmaceutical group Servier.\"For patients with uveal melanoma, these results potentially offer a new treatment option that delivers a significant clinical advancement in both progression-free survival and overall response rate versus currently available therapies,\" Chief Executive Yujiro Hata said.Ideaya said that, based on these results, it will target the submission of a new drug application to the Food and Drug Administration in the second hal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDYA":"IDEAYA Biosciences","BK4139":"生物科技"},"translate_title":"Ideaya Biosciences股价因试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Ideaya Biosciences climbed after the company announced what it called positive top-line results from its melanoma-treatment trial. \n\n\n  The stock jumped 36%, to $41.52, in premarket trading Monday. Through Friday's close, shares are up 82% over the past year. \n\n\n  The oncology company said before the bell that its treatment, darovasertib, used in combination with crizotinib, resulted in a statistically significant improvement in median progression-free survival in patients with a certain type of melanoma in a Phase 2/3 registrational study with pharmaceutical group Servier. \n\n\n  \"For patients with uveal melanoma, these results potentially offer a new treatment option that delivers a significant clinical advancement in both progression-free survival and overall response rate versus currently available therapies,\" Chief Executive Yujiro Hata said. \n\n\n  Ideaya said that, based on these results, it will target the submission of a new drug application to the Food and Drug Administration in the second half of the year. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 13, 2026 06:35 ET (10:35 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}